Clinical Trial Update: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer [Phase 1, Phase 2]

View source ↗

Summary

A combination of AMG 102 with ECX (epirubicin, cisplatin, capecitabine) was evaluated in Phase 1/2 for unresectable locally advanced or metastatic gastric cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• AMG 102 (AMG 102)
• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Epirubicin (epirubicin)

Snippet

Sponsor: Amgen | Conditions: Esophagogastric Junction Adenocarcinoma, Gastric Cancer | Phase 1, Phase 2 | Status: COMPLETED